Fennec Announces Pricing of Public Offering
April 30, 2020 09:16 ET
|
Fennec Pharmaceuticals Inc.
RESEARCH TRIANGLE PARK, N.C., April 30, 2020 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a...
Fennec Announces Proposed Public Offering of Common Shares
April 29, 2020 16:01 ET
|
Fennec Pharmaceuticals Inc.
RESEARCH TRIANGLE PARK, N.C., April 29, 2020 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a specialty pharmaceutical company focused on the development of PEDMARK™ (a...
Fennec Pharmaceuticals Announces FDA Filing Acceptance and Priority Review of New Drug Application for PEDMARK™
April 13, 2020 07:08 ET
|
Fennec Pharmaceuticals Inc.
~ Potential for PEDMARK to be the First Product for the Prevention of Cisplatin-Induced Hearing Loss in Children ~ ~ FDA Grants Priority Review and Sets a Prescription Drug User Fee Act (PDUFA)...
Fennec Announces Issuance of U.S. Patent for Use of PEDMARK™
March 05, 2020 07:00 ET
|
Fennec Pharmaceuticals Inc.
RESEARCH TRIANGLE PARK, N.C., March 05, 2020 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (Nasdaq: FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK™ (a...
Fennec Pharmaceuticals Receives European Medicines Agency Validation for Marketing Authorization Application for Sodium Thiosulfate
February 28, 2020 06:00 ET
|
Fennec Pharmaceuticals Inc.
RESEARCH TRIANGLE PARK, N.C., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (Nasdaq: FENC; TSX: FRX), a specialty pharmaceutical company, today announced that the company’s Marketing...
Fennec Provides Business Update and Announces Fiscal Year 2019 Financial Results
February 14, 2020 06:00 ET
|
Fennec Pharmaceuticals Inc.
NDA (New Drug Application) and Marketing Authorization Application (MAA) completed in February 2020Commercial readiness activities in U.S. underway for potential launch of PEDMARKTM, if approved, in...
Fennec Pharmaceuticals Completes Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for PEDMARK™ and Also Submits Marketing Authorization Application (MAA) to European Medicines Agency
February 11, 2020 06:00 ET
|
Fennec Pharmaceuticals Inc.
RESEARCH TRIANGLE PARK, N.C., Feb. 11, 2020 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (Nasdaq:FENC; TSX: FRX), a specialty pharmaceutical company, today announced it has completed its rolling...
Fennec Provides Business Update and Announces Third Quarter 2019 Financial Results
November 12, 2019 06:00 ET
|
Fennec Pharmaceuticals Inc.
NDA (New Drug Application) for PEDMARKTM to be completed in early 2020Strong financial position with $15.2 million in cash and no debt RESEARCH TRIANGLE PARK, N.C., Nov. 12, 2019 (GLOBE NEWSWIRE)...
Fennec to Present at the 2019 Cantor Global Healthcare Conference on October 4, 2019
October 02, 2019 06:00 ET
|
Fennec Pharmaceuticals Inc.
RESEARCH TRIANGLE PARK, N.C., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a...
Fennec Appoints Jodi A. Cook, PhD to Its Board of Directors
September 24, 2019 06:00 ET
|
Fennec Pharmaceuticals Inc.
RESEARCH TRIANGLE PARK, N.C., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a...